Related Experiment Videos
Mitoxantrone in relapsed and refractory acute leukemia
Abstract:
Mitoxantrone is a relatively new synthetic anthracenedione derivative with intercalating properties. An in vitro study with established leukemia cell lines indicated that DNA strand breaks were caused by mitoxantrone; when these were progressive after the initial insult, the cell line was sensitive to the drug. Clinical trials involved patients with relapsed and/or refractory acute leukemia. None of the patients receiving a single slow infusion of mitoxantrone achieved a complete remission. A five day treatment regimen produced an overall response rate of 48% with a complete remission rate of 25%. Toxicity in these preliminary studies was limited compared to that expected with the anthracycline antibiotics. Alopecia and nausea were the only commonly observed side effects. The trials were too short, however, to evaluate possible cardiac toxicity. Mitoxantrone is an acute and relatively nontoxic agent that merits further study to identify its role in the first line therapy of acute leukemia; such studies are underway.
Insights
Mitoxantrone shows promise in treating acute leukemia, with a five-day regimen yielding a 48% response rate. Further studies are needed to confirm its efficacy and safety, particularly cardiac toxicity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Mitoxantrone is a synthetic anthracenedione derivative with DNA intercalating properties.
- In vitro studies demonstrate mitoxantrone induces DNA strand breaks, correlating with leukemia cell line sensitivity.
Purpose of the Study:
- To evaluate the efficacy and toxicity of mitoxantrone in patients with relapsed or refractory acute leukemia.
- To determine the optimal treatment regimen for mitoxantrone in acute leukemia.
Main Methods:
- In vitro studies using leukemia cell lines.
- Clinical trials involving patients with relapsed/refractory acute leukemia, assessing response rates and side effects.
Main Results:
- A single infusion of mitoxantrone did not result in complete remission.
- A five-day treatment regimen achieved a 48% overall response rate, including a 25% complete remission rate.
- Observed toxicities were limited, primarily alopecia and nausea; cardiac toxicity requires further evaluation.
Conclusions:
- Mitoxantrone is a relatively non-toxic agent for acute leukemia treatment.
- A five-day regimen shows potential efficacy, warranting further investigation in first-line therapy.
- Ongoing studies aim to establish the role of mitoxantrone in acute leukemia treatment protocols.